Glutaminase inhibitor therapy
AssigneeBoard of Regents, The University of Texas System
InventorsTimothy Heffernan, Jeffrey Kovacs, Nakia Spencer, Christopher Bristow
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.
Claims14
A method of identifying a subject's responsiveness to GLS-1 inhibitor therapy and treating cancer in said subject, comprising determination of a low level of expression or concentration of ASNS in said subject and administering one or more glutathione lowering agents to said subject.
A method of treating cancer in a subject who is refractory to platinum-based chemotherapy and has a low level of expression or concentration of ASNS, comprising administering one or more glutathione lowering agents to said subject.
Dependencies are inferred from the claim text.